Chris Bystroff

Chris Bystroff is a Professor in the Department of Biological Sciences at Rensselaer Polytechnic Institute (RPI), affiliated with the Center for Biotechnology and Interdisciplinary Studies (CBIS) and Center for Computational Innovations (CCI). His work bridges computational biology, experimental protein engineering, and global population modeling.

Education:

• Ph.D. in Chemistry, University of California, San Diego (1988)
• B.S. in Chemistry, Carleton College (1983)
• Postdoctoral Researcher, UCSF (1989-1992) in Protein Crystallography
• Postdoctoral Researcher, University of Washington (1995-1999) in Bioinformatics

Professor Bystroff's research spans protein folding dynamics, biosensor development, and contraceptive vaccines. Initially computational, his lab now integrates wet-lab experiments with bioinformatics, notably creating GFP-based biosensors for pathogens like influenza and dengue. His contraceptive vaccine targets CatSper using HPV-derived virus-like particles, while his World4 population model addresses overpopulation as an existential threat. Current projects include HPV-chimeric platforms for cancer immunotherapeutics and glycan-free COVID vaccines.

Recent publications reveal a trajectory from computational protein modeling toward translational biomedical applications, emphasizing rugged fitness landscapes in biosensor design, electrostatic forces in immune activation, and interdisciplinary solutions for fertility control and pandemic preparedness. The work consistently combines algorithm development with experimental validation.

Research funding is secured through NSF, NIH, Rosetta Commons, and private foundations. Collaborations span molecular biology (Prof. Donna E. Crone), computational science (CCI), and biotechnology (CBIS), with emphasis on high-throughput screening and structural vaccinology.

The lab operates within CBIS facilities, leveraging chimeric HPV-L1 platforms for epitope-directed vaccines. Key initiatives include fiber-integrated biosensors, SARS-CoV-2 spike protein engineering, and metastatic cancer biomarker targeting, demonstrating versatile nanoparticle applications.